Compare Amgen, Inc. (AMGN) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Vipshop Holdings Ltd - ADR trades at $13.94 (market cap $6.69B). The key difference: Amgen, Inc. is far larger — about 29.3× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| AMGN | VIPS | |
|---|---|---|
Market Cap | $196.12B | $6.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $20.68 |
52-Week Low | $271.18 | $12.92 |
Enterprise Value | $241.41B | $3.29B |
Dividend Yield | 2.77% | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Vipshop Holdings (VIPS) trades at $13.94, up 0.65% with a bullish technical signal despite mixed earnings history. The stock shows attractive valuation metrics with P/E of 6.36 and P/S of 0.45, supported by solid profitability including 18.43% ROE. Recent Q1 2026 earnings matched expectations while the company pursues growth through outlet store strategies.
The outlook remains positive with analyst consensus favoring Buy ratings (53.57%) and improving cash flow trends. Key risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds, but strong fundamentals and institutional support suggest potential for upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
